Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

An analysis reveals a spike in pro-Russian disinformation networks surrounding the attempt to oust the European Commission ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Serum levels of C1M, a biochemical marker of type I collagen degradation, may predict progression of total joint damage in ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...